NASDAQ · SLDB
Healthcare · Biotechnology
$7.06
Down-$0.14 (-1.98%)
Updated Oct 6, 2026, 11:27 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLDB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
SLDB closed at $7.06 after 20 trading sessions, down 28.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $6.88 | $7.205 | $6.77 | $7.06 | 1.37M |
| Oct 2, 2026 | $7.14 | $7.26 | $6.78 | $6.85 | 1.2M |
| Oct 1, 2026 | $7.14 | $7.245 | $6.91 | $6.98 | 1.58M |
| Sep 30, 2026 | $7.24 | $7.54 | $7.16 | $7.23 | 1.71M |
| Sep 29, 2026 | $7.26 | $7.325 | $6.90 | $7.16 | 1.39M |
| Sep 28, 2026 | $7.14 | $7.345 | $7.095 | $7.28 | 1.41M |
| Sep 25, 2026 | $7.53 | $7.54 | $7.15 | $7.29 | 1.42M |
| Sep 24, 2026 | $7.95 | $8.00 | $7.35 | $7.48 | 1.35M |
| Sep 23, 2026 | $8.89 | $8.91 | $8.001 | $8.02 | 1.09M |
| Sep 22, 2026 | $8.67 | $8.955 | $8.56 | $8.92 | 1.31M |
| Sep 21, 2026 | $9.03 | $9.03 | $8.525 | $8.54 | 1.17M |
| Sep 18, 2026 | $8.87 | $8.97 | $8.635 | $8.91 | 4.09M |
| Sep 17, 2026 | $8.94 | $8.97 | $8.60 | $8.87 | 1.19M |
| Sep 16, 2026 | $8.62 | $8.755 | $8.265 | $8.72 | 2.26M |
| Sep 15, 2026 | $8.69 | $8.69 | $8.16 | $8.37 | 1.51M |
| Sep 14, 2026 | $8.82 | $9.1094 | $8.71 | $8.74 | 1.03M |
| Sep 11, 2026 | $9.205 | $9.365 | $8.655 | $8.70 | 1.11M |
| Sep 10, 2026 | $9.36 | $9.36 | $9.01 | $9.07 | 855.92K |
| Sep 9, 2026 | $9.77 | $9.95 | $9.53 | $9.54 | 646.35K |
| Sep 8, 2026 | $10.00 | $10.09 | $9.58 | $9.93 | 742.82K |
The latest Smart Investors Daily articles mentioning SLDB.
Company
Market Activity
Research & News
SLDB research
Company profile and research snapshot.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | RBC Capital | Outperform | — |
| Sep 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 27, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 21, 2026 | Truist Securities | Buy | — |
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 25, 2026
Solid Biosciences is leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. Learn more about SLDB stock here.
Benzinga · Sep 16, 2026
Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.
Benzinga · Sep 16, 2026
RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.
Benzinga · Sep 14, 2026
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $25 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLDB.
